Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Quince Therapeutics, Inc.QNCX · Entity 7403 | Director | December 26, 2025 | December 29, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Quince Therapeutics, Inc.
Report date December 26, 2025 · Filed December 29, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 39,179 |
Reported balance
After 2025-12-26 transaction · row 1
1 source rowRow 1 · 2025-12-26 · Sale · Disposed 50,000 · Balance 39,179 F1: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
INTERCEPT PHARMACEUTICALS, INC.
Report date November 08, 2023 · Filed November 13, 2023
Section 16 reporting ended · disclosed 2023-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-11-08 · Other · Disposed 25,487 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-11-08 · Disposition to issuer · Disposed 8,111 · Balance 0 F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.08 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-11-08 · Disposition to issuer · Disposed 12,089 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.82 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-11-08 · Disposition to issuer · Disposed 12,790 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.17 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-11-08 · Disposition to issuer · Disposed 12,547 · Balance 0 F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $210.36 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-11-08 · Disposition to issuer · Disposed 551 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $183.62 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-11-08 · Disposition to issuer · Disposed 1,750 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $145.22 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-11-08 · Disposition to issuer · Disposed 1,598 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $122.01 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-11-08 · Disposition to issuer · Disposed 2,036 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $85.12 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2023-11-08 · Disposition to issuer · Disposed 2,748 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $82.25 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2023-11-08 · Disposition to issuer · Disposed 2,174 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $72.74 | Direct | 0 |
Reported balance
After 2023-11-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-11-08 · Disposition to issuer · Disposed 2,966 · Balance 0 F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.
F2: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time.
F4: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time.
F5: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 26, 2025 Filed Dec 29, 2025 17:36 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | SaleCommon Stock | 50,000 | $3.47 | $173,500.00 |
DisclosureSEC source: 0000912282-25-001469 · form4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,179 F1 · price: The sale price reported above is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.45 to $3.56, inclusive. The reporting person undertakes to provide to Quince Therapeutics, Inc., any security holder of Quince Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 04, 2025 Filed Jun 6, 2025 17:38 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantDirector Stock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $1.09 | $0.00 |
DisclosureSEC source: 0000912282-25-000623 · form4.xml · derivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to the option shall vest 100% on the one-year anniversary of the grant date. The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the issuer's Outside Director Compensation Policy. Read SEC document |
| October 23, 2024 Filed Dec 29, 2025 17:34 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | OtherCommon Stock | 8,918 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000912282-25-001468 · form4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,179 F1 · kind: In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024. F1 · price: In connection with the Stock Purchase Agreement between the Issuer and EryDel Italy Inc.announced in the Issuer's 8-k filed with the Securities and Exchange Commission on July 24, 2023 (the "Acquisition"), 10% of the shares of common stock of the Issuer issued to the Reporting Person in connection with the Acquisition were held back for one (1) year following closing and released to the Reporting Person on October 23, 2024. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:57 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001415889-24-016088 · form4-06082024_120618.xml · derivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,966 | Not disclosed Strike: $72.74 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 12 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,966 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,174 | Not disclosed Strike: $82.25 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 11 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,174 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,748 | Not disclosed Strike: $85.12 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 10 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,748 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 2,036 | Not disclosed Strike: $122.01 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 9 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,036 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 1,598 | Not disclosed Strike: $145.22 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 8 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,598 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 1,750 | Not disclosed Strike: $183.62 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 7 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,750 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 551 | Not disclosed Strike: $210.36 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 6 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 551 shares Expires not disclosed F5 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. F5 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,547 | Not disclosed Strike: $9.17 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 5 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,547 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,790 | Not disclosed Strike: $16.82 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 4 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,790 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerOption to Purchase Common Stock · Derivative | 12,089 | Not disclosed Strike: $17.08 | Not disclosed |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · derivative · entry 3 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,089 shares Expires not disclosed F4 · price: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.exercise_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. F4 · derivative.expiration_date: Pursuant to the Merger Agreement, each option to purchase shares of Company Common Stock that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Offer Price, was cancelled and converted into the right to receive a cash payment (without interest, and less any applicable withholding taxes) equal to (A) the excess of (x) the Offer Price over (y) the exercise price payable per share of Company Common Stock under such option, multiplied by (B) the total number of shares of Company Common Stock subject to such option immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | Disposition to issuerCommon Stock | 8,111 | $19.00 | $154,109.00 |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · nonDerivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F2 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the RSU. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the contingent right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Company Common Stock subject to such RSU. Such payment right will vest and become payable in accordance with vesting schedule (including any vesting acceleration provisions) that applied to the corresponding portion of the applicable RSUs immediately prior to the Effective Time. Read SEC document |
| November 08, 2023 Filed Nov 13, 2023 14:46 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | OtherCommon Stock | 25,487 | $19.00 | $484,253.00 |
DisclosureSEC source: 0001104659-23-117110 · tm2330435-10_4seq1.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 26, 2023, among the Issuer, Alfasigma S.p.A. ("Alfasigma"), and Interstellar Acquisition Inc., a wholly owned subsidiary of Alfasigma ("Purchaser"), pursuant to which Purchaser completed a tender offer for shares of common stock of the Issuer ("Company Common Stock") and thereafter merged with and into the Issuer, effective as of November 8, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of Company Common Stock was cancelled and converted into the right to receive $19.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. Read SEC document |
| October 23, 2023 Filed Oct 24, 2023 19:46 UTC | Quince Therapeutics, Inc. QNCX · Entity 7403 | GrantEmployee Stock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001209191-23-053510 · doc4.xml · derivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2033-10-22 F1 · derivative.exercise_date: The shares subject to the stock option shall vest in equal annual installments over the three-year period following the grant date of October 23, 2023, subject to the Reporting Person's continued service as a member of the Board of Directors of the Issuer as of each such vesting date. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,547 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001104659-23-064846 · tm2317083-9_4seq1.xml · derivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,547 Underlying: Common Stock · 12,547 shares Expires 2033-05-24 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| May 24, 2023 Filed May 25, 2023 20:40 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 8,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-064846 · tm2317083-9_4seq1.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,598 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:18 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,790 | $0.00 Strike: $16.82 | $0.00 |
DisclosureSEC source: 0001104659-22-065918 · tm2217184-7_4seq1.xml · derivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,790 Underlying: Common Stock · 12,790 shares Expires 2032-05-25 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 25, 2022 Filed May 27, 2022 16:18 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,737 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-065918 · tm2217184-7_4seq1.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,487 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2023 Annual Meeting of Stockholders. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 12,089 | $0.00 Strike: $17.08 | $0.00 |
DisclosureSEC source: 0001104659-21-075215 · tm2118118-2_4seq1.xml · derivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,089 Underlying: Common Stock · 12,089 shares Expires 2031-05-27 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 7,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-075215 · tm2118118-2_4seq1.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,750 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2022 Annual Meeting of Stockholders. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:05 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,966 | $0.00 Strike: $72.74 | $0.00 |
DisclosureSEC source: 0001104659-20-068537 · tm2021501d8_4.xml · derivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,966 Underlying: Common Stock · 2,966 shares Expires 2030-05-28 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 19:05 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-068537 · tm2021501d8_4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,721 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2021 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,174 | $0.00 Strike: $82.25 | $0.00 |
DisclosureSEC source: 0001144204-19-031954 · tv524020_4.xml · derivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,174 Underlying: Common Stock · 2,174 shares Expires 2029-06-20 F2 · derivative.exercise_date: All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 19:01 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,570 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-031954 · tv524020_4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,126 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2020 Annual Meeting of Stockholders. Read SEC document |
| May 14, 2019 Filed May 14, 2019 19:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | PurchaseCommon Stock | 1,200 | $83.50 | $100,200.00 |
DisclosureSEC source: 0001144204-19-026103 · tv521396_4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,556 Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,748 | $0.00 Strike: $85.12 | $0.00 |
DisclosureSEC source: 0001144204-18-035414 · tv496981_4.xml · derivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,748 Underlying: Common Stock · 2,748 shares Expires 2028-06-20 F2 · derivative.exercise_date: All of the shares subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 20, 2018 Filed Jun 22, 2018 17:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,787 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-18-035414 · tv496981_4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,356 F1 · shares: Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2019 Annual Meeting of Stockholders. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantOption to Purchase Common Stock · Derivative | 2,036 | $0.00 Strike: $122.01 | $0.00 |
DisclosureSEC source: 0001144204-17-035030 · v470071_form4.xml · derivative · entry 2 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,036 Underlying: Common Stock · 2,036 shares Expires 2027-06-27 F1 · derivative.exercise_date: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
| June 27, 2017 Filed Jun 29, 2017 21:00 UTC | INTERCEPT PHARMACEUTICALS, INC. ICPT · Entity 108343 | GrantCommon Stock | 1,423 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-035030 · v470071_form4.xml · nonDerivative · entry 1 Benatti Luca · CIK 0001613842 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,569 F1 · shares: The 1,423 shares of restricted stock and the shares of 2,036 shares of common stock underlying the option will each fully vest on the one-year anniversary of the date of grant (the "Anniversary Date"), subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"); provided, however, if the date of the next subsequent annual meeting of stockholders (starting from the 2018 annual meeting) is held prior to the Anniversary Date in that year, the annual vesting for such year shall occur on the day immediately preceding the date of the annual meeting in such year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.